Skip to content
Medical Health Aged Care

PSA launches training for extended supply of oral contraceptive

Pharmaceutical Society of Australia (PSA) 2 mins read

7 September 2023

This Women’s Health Week the Pharmaceutical Society of Australia (PSA) has launched the NSW – Contraception Essentials training as onboarding begins for the next stage of the New South Wales Pharmacy Trial.

The statewide trial, run by the University of Newcastle, authorises pharmacists participating in the trial to continue a prescription for the resupply of a certain oral contraceptives for eligible women aged from 18 to 35 years.

Pharmacists must meet specific requirements to be eligible for participation, and completing the appropriate training is mandatory.

PSA New South Wales President Luke Kelly FPS urged pharmacists to complete their training with PSA ahead of the trial’s start date.

“Improving safe access to contraception is essential to improving health care for all Australians,” Mr Kelly said.

“PSA is proud to be leading the way in pharmacist education and supporting the development of pharmacy scope of practice.

“PSA has developed a comprehensive training course tailored to the NSW oral contraceptive trial, arming pharmacists with the latest clinical information and giving them the skills and knowledge for the continuation of appropriate contraception.

“This is about making sure that Australians can access contraception when and where they need it,” Mr Kelly concluded.

NSW Pharmacists can now enrol in the NSW – Contraception Essentials training program here.

For more information on the NSW Pharmacy Trial, visit NSW Health.

 

Media contact:   Georgia Clarke   M: 0480 099 798      E: [email protected]

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s 36,000 pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.

Follow us on socials:      Facebook     Twitter      LinkedIn     Instagram

Media

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.